ubmslateCN-logo-ubm

CN Mobile Logo

Search form

Topics:

Leukemia & Lymphoma

Leukemia & Lymphoma

Significant progress has been made in the treatment of chronic lymphocytic leukemia with the addition of options such as the tyrosine kinase inhibitor ibrutinib, the monoclonal antibody obinutuzumab, and the BCL2 inhibitor venetoclax.

Adolescents and young adults with leukemia experienced inferior outcomes compared with children, especially if they were treated outside of a specialized cancer center.

Patients with chronic lymphocytic leukemia who discontinue treatment with ibrutinib due to disease progression or transformation had significantly worse survival compared with patients who discontinued therapy because of intolerance.

The FDA recently approved the oral BTK inhibitor ibrutinib for the treatment of patients with relapsed or refractory marginal zone lymphoma who require systemic therapy and have had at least one prior anti-CD20 therapy.

CML patients who have high expression of the T-cell inhibitory receptor (CTLA-4)-ligand CD86 on plasmacytoid dendritic cells have a higher risk of relapsing after discontinuing therapy with a tyrosine kinase inhibitor.

The addition of clofarabine to standard induction therapy for newly diagnosed acute myeloblastic leukemia reduced the probably of relapse but increased toxicity and had no effect on survival.

Here we review the role of interim PET/CT in diffuse large B-cell lymphoma (DLBCL), and also explore the question of whether new approaches to quantitative assessment improve the prognostic value of interim PET scans in both Hodgkin lymphoma and DLBCL.

Pages

Subscribe to Leukemia & Lymphoma on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.